YONG Tai Bhd is finalising its plans for the commercialisation of it COVID-19 vaccine with Shenzhen Kangtai Biological Products Co Ltd (SZKT) through its latest partnerships with Tiong Nam Logistics Solutions Sdn Bhd and Healthcliqs Sdn Bhd (Healthcliqs).
The tourism-related property developer has put its plan in motion for the distribution of its vaccine by engaging Tiong Nam to provide total logistics services which include transportation, warehouse space and delivery of pharmaceutical products.
Additionally, Yong Tai would also collaborate with digital healthcare solution provider Healthcliqs to facilitate the view and order for all range of pharmaceutical products under the latter’s solution system.
The partnership with Healthcliqs would enable Yong Tai to have an immediate access to more than 4,000 general practitioners (GPs) nationwide for the marketing of its medical products.
According to Yong Tai’s CEO Datuk Wira Boo Kuang Loon, these partnerships would enable the company to gain immediate access to the market that needs the vaccine as well as the critical storage and logistic services for the delivery of vaccine (upon the successful phase III clinical trial and registration with the relevant authorities).
“A lot of planning has been done and we will be investing about RM15 to RM20 mil into the phase III clinical trial of the vaccine,” Boo commented on the Yong Tai-SZKT tie-up that can potentially culminate in a minimum supply of 20 million COVID-19 vaccine doses.
“While there are other vaccines in the market already such as the one developed by Pfizer, AstraZeneca Plc and even China’s Sinovac Biotech Ltd, the supply would not be enough for everyone in the near future.”
Commenting on its collaboration with Tiong Nam, Boo said it is important that a strong logistic service provider is involved given the difficulty in storage and delivery of the vaccine.
Meanwhile, the Yong Tai’s collaboration with Healthcliqs would help the group to reach medical providers seamlessly and on a timely manner once the vaccine is approved for utilisation and made available. – Jan 6, 2021
